Hiro-LS, PatSnap's biopharmaceutical AI model, integrates the proprietary PharmaGPT, a large-scale AI model with 70 billion parameters.

KaliVir Immunotherapeutics administers initial dose in Phase 1/1b trial for VET3-TGI targeting advanced solid tumors.

Oct 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

AstraZeneca enhances its heart health portfolio by securing a deal for a new pre-clinical therapy to lower lipids.

Intellia Therapeutics has begun the HAELO Phase 3 trial for NTLA-2002, a potential CRISPR gene editing treatment for hereditary angioedema.

Vincerx shares encouraging early clinical results from its ongoing Phase 1 study of VIP943, along with updates on its pipeline and corporate developments.

Boehringer Ingelheim has revealed that survodutide (BI 456906) has received the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA).

Halia Therapeutics revealed the initial dosing of HT-4253, an innovative oral LRRK2 inhibitor aimed at reducing neuroinflammation in Alzheimer's, in a healthy participant.

MediLink Therapeutics announced a partnership for a global clinical trial and a supply agreement with Amgen Inc. Under this agreement.

Oct 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

TiumBio announced that it has administered the first dose to a patient in its Phase 2 clinical study of TU2218.

Oct 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.